Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma

Complete title: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant

Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with lp/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Research Study Number 8078
Principal Investigator George Laramore, MD, PhD
Phase III

Research Study Description

Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving temozolomide alone, radiation followed by PCV, or temozolomide together with radiation therapy followed by temozolomide is more effective in treating anaplastic glioma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 8078
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Brain Cancer; Central Nervous System (CNS); Glioma; Solid Tumors; Neoplasms; Astrocytoma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials